Skip to main content
Clinical Trials/NCT01612221
NCT01612221
Completed
Phase 2

A Phase II Placebo-controlled Intervention Trial of Oral N-acetylcysteine (NAC) for Protection of Human Nevi Against UV-induced Oxidative Stress/Damage in Vivo

University of Utah1 site in 1 country100 target enrollmentStarted: September 2012Last updated:

Overview

Phase
Phase 2
Status
Completed
Enrollment
100
Locations
1
Primary Endpoint
UV-induced Oxidative Stress in Irradiated and Unirradiated Nevi

Overview

Brief Summary

This is a phase II intervention to propose a new melanoma chemoprevention agent. The investigators believe oxidative stress/damage in nevi is a probable indication for melanoma risk, and propose that reduced melanoma risk in humans can be inferred by protection of nevi from ultraviolet light (UV)-induced oxidative changes. The investigators will 1) evaluate whether administration of NAC around the time of UV exposure will reduce melanoma risk in high-risk patient populations with genetic susceptibility to UV-induced oxidative stress, and 2) examine key genetic variants that will identify which individuals are most likely to benefit from chemoprotection.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Prevention
Masking
Triple (Participant, Care Provider, Investigator)

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Must have at least 2 nevi (each \>6 mm diameter) not clinically suspicious for melanoma that can be biopsied.
  • Must be able to receive informed consent and sign an approved consent form that conforms to federal and institutional guidelines.

Exclusion Criteria

  • The patient is a minor (\< 18 years old).
  • The patient cannot speak/understand English or Spanish. (NOTE: A Spanish consent form and certified interpreter can be made available if needed)
  • The patient is pregnant. (NOTE: All female patients who have not had a hysterectomy and are not post-menopausal (i.e. post-menopausal for 1 year and not of child-bearing potential) will have a urine pregnancy test.)
  • The patient is a prisoner, critically or mentally ill, or otherwise incapacitated or considered vulnerable.
  • The patient has history of allergic reaction to NAC.
  • The patient has history of severe asthma.
  • The patient has been taking NAC or any other oral antioxidant.
  • The patient has recent history (i.e., 3 months) of sunless tanning (tanning bed) or extensive sunburn.

Arms & Interventions

Patients receiving N-acetylcysteine

Experimental

Patients receiving NAC (N-acetylcysteine)

Intervention: N-acetylcysteine (Drug)

Placebo Group

Placebo Comparator

Participants not receiving NAC (N-acetylcysteine)

Intervention: Placebo arm (Other)

Outcomes

Primary Outcomes

UV-induced Oxidative Stress in Irradiated and Unirradiated Nevi

Time Frame: 3.5 years

Differences in the median percent nevus with 8-OG expression in UV-irradiated nevi compares with unirradiated nevi.

Secondary Outcomes

  • Transcriptional Markers of UV-induced Oxidative Stress in Nevi(3.5 years)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials